Yao Ming Kangde (02359) spent about 30 million euros to win a 3.22% share of the French Biomedical Fund

Zhitong Finance App News, Yao Ming Kangde (02359) announced that on December 18, 2025, WuXi Lux Holding, a wholly-owned subsidiary of the company, signed a subscription agreement with Jeito Capital S.A.S. (hereinafter referred to as the “management company” or “Jeito Capital”), agreeing that WuXi Lux Holding will pledge a Class A share of 10 million euros in the investment fund, corresponding to the raised investment 1.07% of the fund's share. On the same day, WuXi Lux Holding and WuXi PharmaTech Healthcare Fund I L.P. (hereinafter referred to as “WuXi Fund I”) signed a transfer agreement (hereinafter referred to as the “Transfer Agreement”), agreeing that WuXi Lux Holding will transfer the 20 million euro fund share held by WuXi Fund I based on the sum of the net asset value and unfunded pledges of the latest investor account.

After the completion of the transfer agreement and subscription agreement, WuXi Lux Holding will hold a total Class A share of 30 million euros in investment funds, accounting for about 3.22% of the share of the raised investment funds. As of the date of this announcement, WuXi Lux Holding has not paid the investment amount. Subsequently, WuXi Lux Holding will use its own funds to fulfill the payment obligation of the transfer amount and subsequent investment amount as agreed in the subscription agreement and transfer agreement.

The investment fund is formed in accordance with French law and targets innovative companies with the potential to become global leaders in the field of treatment. An early-growing enterprise focusing on biopharmaceuticals with clear clinical needs and commercialization potential. The size of the investment fund does not exceed 1.2 billion euros. WuXi Lux Holding has raised about 931 million euros in investment funds after this additional 10 million euros in pledges.

Jeito Capital's investment management team has excellent investment and portfolio management capabilities. The company believes that the management team's rich experience in biomedical company management and operation, years of industrial resources, and innovative fund operation models can provide key growth capital and operational improvement guidance for European biomedical startups. Innovative companies in the biomedical field that Jeito Capital focuses on are an important potential customer group for the company. This investment can enhance the company's in-depth understanding of the latest developments in the European biomedical sector and provide forward-looking guidance for the company to expand the European market. On the premise of guaranteeing the capital required for daily business development, the company uses its own funds to participate in pledging investment fund shares. This investment will not have a significant impact on the company's financial situation and operating results.